In this June 2019 article, Stephanie Oestreich, Executive Vice President, North American BRIDGEs Partnerships at Evotec SE, examines the reasoning behind creating LAB50, and the aspirations for the collaboration between Evotec and MaRS Innovation: Accelerating Toronto’s Academic Innovation through LAB150, June 2019
Category: Uncategorized
Two New Projects: Cystic Fibrosis and Respiratory Syncytial Virus
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) — MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both…
A New Paradigm in Drug Discovery
The initiative, launched by MaRS Innovation and Evotec AG in September 2017, seeks to bridge academic research, translation and commercialization. Authors: Rafi Hofstein, President and CEO of MaRS Innovation, and Werner Lanthaler, President and CEO of Evotec AG. Published by Global University Venturing December 2017.…